Key Points
- Collegium EVP David Dieter sold 13,976 shares on March 18 at an average price of $34.92 for proceeds of $488,041.92, cutting his stake by 15.35% to 77,071 shares (≈$2.69M).
- Collegium to acquire AZSTARYS from Corium in a deal reported up to $650–$785M; the asset is expected to add over $50M pro‑forma net revenue in H2 2026 and be accretive to adjusted EBITDA, but the cash plus a $300M delayed‑draw term loan raises near‑term leverage and integration risks.
- EPS miss and analyst view: Collegium reported Q4 EPS of $2.04 vs. $2.20 expected (revenue slightly below consensus), and analysts rate the stock a "Moderate Buy" with an average price target of $53.40.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) EVP David Dieter sold 13,976 shares of Collegium Pharmaceutical stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total transaction of $488,041.92. Following the completion of the transaction, the executive vice president directly owned 77,071 shares in the company, valued at approximately $2,691,319.32. The trade was a 15.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Collegium Pharmaceutical Trading Down 2.2%
NASDAQ:COLL opened at $35.49 on Friday. The firm has a market capitalization of $1.13 billion, a P/E ratio of 20.75 and a beta of 0.67. The company has a quick ratio of 1.48, a current ratio of 1.57 and a debt-to-equity ratio of 2.59. The company has a fifty day moving average of $43.26 and a 200 day moving average of $41.88. Collegium Pharmaceutical, Inc. has a 52 week low of $23.23 and a 52 week high of $50.79.
Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by ($0.16). The firm had revenue of $205.45 million during the quarter, compared to the consensus estimate of $206.36 million. Collegium Pharmaceutical had a return on equity of 98.65% and a net margin of 8.05%.Collegium Pharmaceutical's revenue was up 12.9% on a year-over-year basis. During the same period last year, the business earned $1.77 EPS. On average, research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.
Analysts Set New Price Targets
A number of research analysts have commented on the company. Barclays lowered their price target on Collegium Pharmaceutical from $58.00 to $56.00 and set an "overweight" rating for the company in a research report on Friday, January 9th. Wall Street Zen lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 28th. Needham & Company LLC reissued a "buy" rating and set a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday. Truist Financial set a $58.00 target price on Collegium Pharmaceutical in a report on Tuesday, February 10th. Finally, Weiss Ratings lowered Collegium Pharmaceutical from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Thursday, March 5th. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Collegium Pharmaceutical presently has an average rating of "Moderate Buy" and an average price target of $53.40.
Check Out Our Latest Stock Report on Collegium Pharmaceutical
Hedge Funds Weigh In On Collegium Pharmaceutical
A number of institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp grew its holdings in shares of Collegium Pharmaceutical by 3.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 249,875 shares of the specialty pharmaceutical company's stock worth $7,389,000 after acquiring an additional 7,614 shares during the period. Versor Investments LP purchased a new position in shares of Collegium Pharmaceutical in the 3rd quarter valued at approximately $1,337,000. Assenagon Asset Management S.A. lifted its stake in shares of Collegium Pharmaceutical by 90.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 195,589 shares of the specialty pharmaceutical company's stock valued at $6,844,000 after purchasing an additional 92,898 shares during the period. Ballast Asset Management LP boosted its position in shares of Collegium Pharmaceutical by 31.1% during the third quarter. Ballast Asset Management LP now owns 114,315 shares of the specialty pharmaceutical company's stock valued at $4,000,000 after purchasing an additional 27,109 shares in the last quarter. Finally, Eastern Bank grew its stake in Collegium Pharmaceutical by 487.5% in the third quarter. Eastern Bank now owns 54,843 shares of the specialty pharmaceutical company's stock worth $1,919,000 after purchasing an additional 45,508 shares during the period.
Key Stories Impacting Collegium Pharmaceutical
Here are the key news stories impacting Collegium Pharmaceutical this week:
- Positive Sentiment: Collegium agreed to acquire AZSTARYS from Corium, adding a differentiated ADHD medicine to its portfolio; company says the asset is expected to generate over $50M in pro‑forma net revenue in H2 2026, offers patent protection into 2037, and the deal is expected to be immediately accretive to adjusted EBITDA. Collegium to Acquire AZSTARYS from Corium Therapeutics (GlobeNewswire)
- Positive Sentiment: Sell‑side support strengthened: HC Wainwright reaffirmed a Buy with a $60 PT and Needham reaffirmed Buy with a $56 PT — both imply substantial upside vs. the recent share price, which can underpin investor confidence. Analyst Coverage (Benzinga)
- Neutral Sentiment: Conference call and management discussion transcripts are available for investors seeking details on deal economics and integration plans. Acquisition Discussion Transcript (Seeking Alpha)
- Neutral Sentiment: FDA news elsewhere in the pharma sector: PharmExec reports approval of Wegovy HD (Novo Nordisk) — relevant for sector context but not directly tied to Collegium’s ADHD/pain-focused franchise. FDA Approves Wegovy HD (PharmExec)
- Neutral Sentiment: Public press coverage shows deal price described with varying figures (reports cite up to $785M and also $650M headlines) — read releases for definitive terms. Collegium to buy AZSTARYS for up to $785M (MSN)
- Negative Sentiment: The acquisition costs and financing raise near‑term financial risk: the deal is being funded from cash on hand plus a previously announced $300M delayed‑draw term loan, which increases leverage for a company that already shows a relatively high debt/equity ratio; investors may worry about cash burn, integration execution and balance‑sheet pressure. Deal Coverage (FiercePharma)
- Negative Sentiment: Recent quarterly results (Feb. 26) showed a slight revenue and EPS miss vs. consensus, which combined with the large acquisition outlay can pressure near‑term sentiment as investors await proof the deal accelerates growth. Earnings Summary (Benzinga)
- Neutral Sentiment: Reported short‑interest data appears anomalous (shows zero shares), so it does not provide a meaningful read into market positioning at this time.
About Collegium Pharmaceutical
(
Get Free Report)
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company's core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.
The company's principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
